High-quality products
Reliable performance
In Vivo Pharmacodynamic Evaluation of Calu1 Cell Line Based Lung Cancer (CAT#: STEM-AE-0078-LGZ)
Introduction
Lung cancer is the most common primary malignant tumor of lung. Most lung cancer originates from the bronchial mucosal epithelium, so it is also called bronchial lung cancer. Lung cancer can spread around and even throughout the body. The distribution of lung cancer is more in the right lung than in the left lung, in the upper lobe than in the lower lobe, and cancer can occur from the main bronchus to the bronchioles. Originated from the main bronchus, bronchus lobar lung cancer, close to the hilum of the lung, known as central type lung cancer; Lung cancer originating below the bronchus of the lung segment, located in the surrounding part of the lung, known as peripheral lung cancer.
Principle
In vivo activity is the gold standard for the evaluation of drug biological activity, and it is the first verification of non-human comprehensive activity. In vivo pharmacodynamic evaluation plays a decisive role in the confirmation of candidate molecules and the screening of clinical target indications, and is an indispensable link in the development of new drugs. We provide a variety of disease animal models including inflammation, immunity, metabolism, etc., to meet the needs of different new drug research and development projects of customers, and accept customized services.
In vivo pharmacodynamic evaluation, as the basic research of new drugs, is carried out on animals. It is to verify the effect of drugs with the comprehensive participation of a number of other factors, and to understand the effect of drugs on a certain part of the body by comparing and analyzing the animal signs, in vitro organs, blood components, histone expression and tissue changes before and after drug administration.
In vivo pharmacodynamic evaluation, as the basic research of new drugs, is carried out on animals. It is to verify the effect of drugs with the comprehensive participation of a number of other factors, and to understand the effect of drugs on a certain part of the body by comparing and analyzing the animal signs, in vitro organs, blood components, histone expression and tissue changes before and after drug administration.
Applications
Lung Cancer
Procedure
1. Disease model construction.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.
Materials
• Sample Type: liquid or powder
Notes
Oncology efficacy Service package:
In vivo syngeneic model
In vivo CDX model
In vivo PBMC humanized model
In vivo transgenic mouse model
In vivo orthotropic or Metastasis tumor model
In vivo syngeneic model
In vivo CDX model
In vivo PBMC humanized model
In vivo transgenic mouse model
In vivo orthotropic or Metastasis tumor model
Other recommended products
-
In Vivo Pharmacodynamic Evaluation of B-hC5AR2 Mice (GPCR Humanized Mice) (CAT#: STEM-AE-0548-LGZ)
-
In Vivo Pharmacodynamic Evaluation of B-hMERTK Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0301-LGZ)
-
In Vivo Pharmacodynamic Evaluation of B-hITGA5 Mice (Humanized Mice) (CAT#: STEM-AE-0618-LGZ)
-
In Vivo Pharmacodynamic Evaluation of B-hCD3E/hHER2 Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0395-LGZ)
-
In Vivo Pharmacodynamic Evaluation of B-hROR1 MC38 Cells Induced Tumor Models (CAT#: STEM-AE-0179-LGZ)
-
In Vivo Pharmacodynamic Evaluation of B-hOX40/hOX40L Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0378-LGZ)
-
In Vivo Pharmacodynamic Evaluation of B-Tg(hLILRB1/hLILRB4) Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0377-LGZ)
-
In Vivo Pharmacodynamic Evaluation of B-hCD23 Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0237-LGZ)
Wide range of applications
For various laboratory needs
Expert support
Professional service team
Fast delivery
Global shipping